Shots:

• The P-III KEYNOTE-826 trial evaluates Merck’s Keytruda (200mg- IV- q3w for up to 35 cycles) + Pt-based CT vs PBO + CT with/out bevacizumab in 617 patients aged b/w 22- 82yrs. with persistent- recurrent- or metastatic cervical cancer
• The results showed a 33% reduction in the risk of death; m-OS (24.4 vs 16.5mos.)- m-PFS (10.4 & 8.2 mos.); ORR (65.9% & 50.8%); m-DoR (18.0 & 10.4mos.)- TRAEs grade ≥3 (68.4% & 64.1%)- discontinuation of the treatment due to TRAEs (31.3% & 3.3%) in patients with combination therapy. The results were consistent with/out bevacizumab use
• Keytruda is an anti- PD-1 therapy that increases the ability of the body’s immune system to help detect and fight tumor cells

  Ref: Merck | Image: Merck